Amneal Q2 2022: net loss $121M, revenue +5% to $559M; Opana settlement charge $263M

Amneal Pharmaceuticals, Inc.

2022-Q2 EPS reported -$0.82 revenue$1,056,988,000

Q2 2022 net revenue $559M (+5% YoY); GAAP net loss $121M vs net income $15M in Q2 2021.
Adjusted EBITDA $135M (-6% YoY); adjusted diluted EPS $0.19 vs $0.23 in prior year.
Pre-tax charge of $263M for Opana ER antitrust litigation settlement recorded.
2022 adjusted EBITDA guidance updated; specific figure not disclosed in provided excerpt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.